Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dogwood Therapeutics ( (DWTX) ) has shared an announcement.
On March 26, 2026, Dogwood Therapeutics issued a first-quarter shareholder letter detailing significant progress across its clinical pipeline and financing. The company highlighted enrollment of 145 patients in its Phase 2b HALT-CINP study of Halneuron® for chemotherapy-induced pain, ongoing work to develop a synthesized version of Halneuron® for Phase 3 and commercialization, and continued advancement of SP16 IV as a potential treatment for chemotherapy-related neuropathy.
During the quarter, Dogwood raised $12.5 million, extending its cash runway through the expected release of final Halneuron® Phase 2b data this fall, while the forthcoming SP16 IV Phase 1b trial is fully funded by a National Cancer Institute grant. The company outlined 2026 milestones including full recruitment of the HALT-CINP study by summer, initiation of SP16 IV Phase 1b dosing by mid-2026, and submission of end-of-Phase-2, manufacturing, and Phase 3 plans for Halneuron® to the FDA by year-end, positioning the firm for a pivotal transition toward late-stage development in non-opioid oncology pain and neuropathy.
The most recent analyst rating on (DWTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page.
Spark’s Take on DWTX Stock
According to Spark, TipRanks’ AI Analyst, DWTX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn) and bearish technicals (price well below key moving averages with negative momentum). Corporate events provide a partial offset via added financing and pipeline progress, but valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on DWTX stock, click here.
More about Dogwood Therapeutics
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on non-opioid medicines for pain and neuropathic disorders, particularly cancer-related and chemotherapy-induced pain and neuropathy. Its pipeline centers on two first-in-class candidates, Halneuron®, a fast track-designated NaV 1.7 analgesic in Phase 2b trials for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist aimed at treating neuropathy and nerve damage from chemotherapy.
The company’s research emphasizes targeted, non-opioid mechanisms that modulate pain transmission and inflammation, with SP16 IV showing preclinical anti-inflammatory and tissue-repair signals. Dogwood’s largest shareholder is affiliated with CK Life Sciences Int’l., listed in Hong Kong, providing a strategic backing as the company advances its clinical programs and prepares for potential later-stage development and commercialization.
Average Trading Volume: 54,911
Technical Sentiment Signal: Sell
Current Market Cap: $77.16M
See more data about DWTX stock on TipRanks’ Stock Analysis page.